1. Agostini ML, Andres EL, Sims AC et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018 Mar 6;9(2):e00221-18. DOI: 10.1128/mBio.00221-18
2. Sheahan TP, Sims AC, Graham RL et al. Broad-spectrum antiviral GS5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396):eaal3653. DOI: 10.1126/scitranslmed.aal3653
3. Sheahan TP, Sims AC, Leist SR et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. DOI: 10.1038/s41467-01913940-6
4. «Singapore approves remdesivir drug for emergency COVID-19 treatment». Reuters. Retrieved 10 June 2020.
5. Wang M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DOI: 10.1038/s41422-020-0282-0
6. FDA Allows For ‘Emergency Use’ of Remdesivir, Experimental Coronavirus Drug (англ.). TIME. ASSOCIATED PRESS (1 May 2020)
7. Herman Steve. Coronavirus Treatment Breakthrough Announced. Voice of America. [Internet]. [cited 2020 April 29]; Available from: https://www.voanews.com/covid-19-pandemic/coronavirus-treatment-breakthrough-announced
8. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. National Institute of Allergy and Infectious Diseases (NIAID) [Internet]. [cited 2020 April 29]; Available from: https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-acceleratesrecovery-advanced-covid-19
9. Воронин Н. Ученые подтвердили эффективность ремдесивира в лечении коронавируса. Би-би-си BBC News Русская служба. [Электронный ресурс]. Доступно по: https://www.bbc.com/russian/news-52490929 Ссылка активна на 30.04.2020
10. Beigel JH et al. Remdesivir for the Treatment of Covid-19 Preliminary Report. N Engl J Med. 2020 May 22;NEJMoa2007764. DOI: 10.1056/NEJMoa2007764
11. Gøtzsche PC. Remdesivir against coronavirus, hope or hype? / Prof. Peter C. Gøtzsche — Copenhagen: Institute for Scientific Freedom [Internet]. [cited 2020 June 1]; Available from: https://www.scientificfreedom.dk/wpcontent/uploads/2020/06/Gøtzsche-Remdesivir-against-coronavirus-hopeor-hype.pdf
12. Goldman JD et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 May 27;NEJMoa2015301. DOI: 10.1056/NEJMoa2015301
13. Search of: Favipiravir — List Results — ClinicalTrials.gov [Internet]. [cited 2020 July 09]; Available from: https://clinicaltrials.gov/ct2/results?cond=&term=&type=&rslt=&age_v=&gndr=&intr=Remdesivir
14. World Health Organization (WHO) (2020) Clinical management of COVID-19. Interim Guidance. 27 May. [Internet]. [cited 2020 June 09]; Available from: https://www.who.int/publications/i/item/clinicalmanagement-of-covid-19
15. Frequently Asked Questions on the Emergency Use Authorization for Remdesivir for Certain Hospitalized COVID-19 Patients [Internet]. [cited 2020 June 09]; Available from: https://www.fda.gov/media/137574/download
16. Caroline Cassels. COVID-19 Update: Elusive Complication, Remdesivir Toxicity. Medscape Medical News. gov [Internet]. [cited 2020 July 08]; Available from: https://www.medscape.com/viewarticle/933623?src=iphone&ref=email#vp_1
17. Государственный реестр лекарственных средств, реестр разрешений на проведение клинических исследований [РКИ]. [Электронный ресурс]. [Электронный ресурс]. Доступно по: https://grls.rosminzdrav.ru/CiPermitionReg.aspx?Torg=ремдесивир Ссылка активна на 09.07.2020
